Clinical Trials | January 11, 2026
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The approval is backed by data showing deep, durable responses and manageable tolerability
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Subscribe To Our Newsletter & Stay Updated
